DK0508756T3 - Stabiliseret vitamin D-præparat - Google Patents

Stabiliseret vitamin D-præparat

Info

Publication number
DK0508756T3
DK0508756T3 DK92303129.8T DK92303129T DK0508756T3 DK 0508756 T3 DK0508756 T3 DK 0508756T3 DK 92303129 T DK92303129 T DK 92303129T DK 0508756 T3 DK0508756 T3 DK 0508756T3
Authority
DK
Denmark
Prior art keywords
active compound
pharmaceutical composition
heat
vitamin
preparation
Prior art date
Application number
DK92303129.8T
Other languages
Danish (da)
English (en)
Inventor
Tetsuro Tabata
Hiroki Itoh
Jun-Ichi Kikuta
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DK0508756T3 publication Critical patent/DK0508756T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK92303129.8T 1991-04-09 1992-04-08 Stabiliseret vitamin D-præparat DK0508756T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7621091 1991-04-09
JP1909992 1992-02-04

Publications (1)

Publication Number Publication Date
DK0508756T3 true DK0508756T3 (da) 1997-03-24

Family

ID=26355908

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92303129.8T DK0508756T3 (da) 1991-04-09 1992-04-08 Stabiliseret vitamin D-præparat

Country Status (14)

Country Link
US (1) US5487900A (OSRAM)
EP (1) EP0508756B1 (OSRAM)
JP (1) JPH05279260A (OSRAM)
KR (1) KR100231633B1 (OSRAM)
AT (1) ATE144424T1 (OSRAM)
AU (1) AU649802B2 (OSRAM)
CA (1) CA2065603C (OSRAM)
DE (1) DE69214704T2 (OSRAM)
DK (1) DK0508756T3 (OSRAM)
ES (1) ES2094290T3 (OSRAM)
GR (1) GR3021892T3 (OSRAM)
IE (1) IE75709B1 (OSRAM)
NZ (1) NZ242271A (OSRAM)
TW (1) TW212761B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701264A1 (de) * 1997-01-16 1998-07-23 Kief Lizenz Verwertungsgesells Heilmittel, enthaltend Betasitosterin und/oder Phytosterol/Betasitosteringemische
AU2001278956B2 (en) * 2000-07-18 2007-04-05 Genzyme Corporation Stabilized 1alpha-hydroxy vitamin d
CA2425367A1 (en) * 2000-08-30 2003-04-07 Chugai Seiyaku Kabushiki Kaisha Oct formulations
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンd化合物を含む薬学的組成物
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2924200C (en) * 2005-10-12 2017-09-05 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
WO2007092755A2 (en) 2006-02-03 2007-08-16 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
EP3335712B1 (en) 2007-04-25 2025-09-10 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP2148661B1 (en) 2007-04-25 2012-12-12 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンd治療法
JP7085105B2 (ja) * 2016-11-10 2022-06-16 日産化学株式会社 ビタミンd3誘導体の製剤
PE20211489A1 (es) 2018-08-31 2021-08-11 Opko Ireland Global Holdings Ltd Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンd↓3類組成物
JPS6217A (ja) * 1985-02-14 1987-01-06 Chugai Pharmaceut Co Ltd 安定な活性型ビタミンd3類製剤
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンd▲下3▼類固型製剤
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンd↓3類含有組成物

Also Published As

Publication number Publication date
US5487900A (en) 1996-01-30
GR3021892T3 (en) 1997-03-31
KR920019346A (ko) 1992-11-19
ATE144424T1 (de) 1996-11-15
EP0508756B1 (en) 1996-10-23
CA2065603A1 (en) 1992-10-10
IE921126A1 (en) 1992-10-21
JPH05279260A (ja) 1993-10-26
EP0508756A1 (en) 1992-10-14
DE69214704T2 (de) 1997-04-17
KR100231633B1 (ko) 1999-11-15
DE69214704D1 (de) 1996-11-28
ES2094290T3 (es) 1997-01-16
CA2065603C (en) 2007-04-03
NZ242271A (en) 1993-10-26
AU1480492A (en) 1992-10-15
TW212761B (OSRAM) 1993-09-11
IE75709B1 (en) 1997-09-10
AU649802B2 (en) 1994-06-02

Similar Documents

Publication Publication Date Title
DK0508756T3 (da) Stabiliseret vitamin D-præparat
CA2027592A1 (en) Solid pharmaceutical preparations of active form of vitamin d_ of improved stability
EP0519428A3 (en) Cyclodextrin composition
ATE79619T1 (de) Arzneimittel.
NO885213D0 (no) Stabiliserte legemidler, fremgangsmŸte til deres fremstilling samt stabile legemiddeltilberedninger.
DK0588539T3 (da) Stabiliserede farmaceutiske præparater indeholdende derivater af vitamin D2 og D3
ITMI922603A1 (it) Composizioni farmaceutiche comprendenti un farmaco, una sostanza polimerica reticolata, un olio ed un agente tensioattivo
AU1033292A (en) Indole piperazine derivatives and pharmaceutical preparations containing such derivatives
DE3576494D1 (de) Polymer-stabilisierende verbindungen und diese enthaltende stabilisierte polymerzusammensetzungen.
NO940523L (no) Nye pyrazin-derivater
FI102028B1 (fi) Pestisidien tablettiformuloinnit
ES2021705B3 (es) Una composicion a base de particulas ceramicas finamente divididas.
SE8600658D0 (sv) Novel composition of matter
CA2063689A1 (en) Ibuprofen lysinate pharmaceutical formulation
DE59101404D1 (de) Topische Präparate.
DE69227612D1 (de) Hexahydrobenzo(f)quinolinone als 5-alpha-reduktase Inhibitoren
ATE145555T1 (de) Neue pharmazeutische formulierung enthaltend spiramycine
DK0384416T3 (da) Farmaceutisk sammensætning indeholdende hydantoinderivat
ATE90942T1 (de) (3-diethylaminopropyl)-1-amino-5methyldipyrido(4,3-b>(3,4-f>indoltrihydrochlori .